Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

81. Growth Monitoring for Children with Chronic Kidney Disease

). However the frequency of measurement we recommend provides significant benefits in our opinion but has a weak evidence base due to a general lack of studies in this area(1D). This guideline is endorsed by The British Society for Paediatric Endocrinology and Diabetes (BSPED), The British Association for Paediatric Nephrology (BAPN) and The Paediatric Renal Interest Nutrition Group (PRING). Stages of Chronic Kidney Disease (CKD) 14 Stage GFR* Description Management 1 > 90 Normal Renal Function (...) and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases study. J Paediatr. 1990; 116: S46 – 54 2. Norman LJ, Coleman JE, MacDonald 1A, Thomsett AM, Watson AR: Nutrition and Growth in relation to severity of renal disease in children, Paediatric Nephrology 2000; 15, 259-65. 3. Kari JA, Gonzalez C, Lederman S, Shaw V, Rees L: Outcome and Growth of Infants with Severe Chronic Renal Failure. Kidney

2019 British Society for Paediatric Endocrinology and Diabetes

82. Interventions for improving sleep quality in people with chronic kidney disease. Full Text available with Trip Pro

Interventions for improving sleep quality in people with chronic kidney disease. Sleep disorders are commonly experienced by people with chronic kidney disease (CKD). Several approaches for improving sleep quality are used in clinical practice including relaxation techniques, exercise, acupressure, and medication.To assess the effectiveness and associated adverse events of interventions designed to improve sleep quality among adults and children with CKD including people with end-stage kidney (...) disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Register of Studies up to 8 October 2018 with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi-randomised RCTs

2019 Cochrane

83. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. Full Text available with Trip Pro

Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. To investigate the relation between preterm birth (gestational age <37 weeks) and risk of CKD from childhood into mid-adulthood.National cohort study.Sweden.4 186 615 singleton live births in Sweden during 1973-2014.Gestational age at birth, identified from nationwide birth records in the Swedish birth registry.CKD, identified from nationwide inpatient and outpatient diagnoses through 2015 (...) males and females and did not seem to be related to shared genetic or environmental factors in families.Preterm and early term birth are strong risk factors for the development of CKD from childhood into mid-adulthood. People born prematurely need long term follow-up for monitoring and preventive actions to preserve renal function across the life course.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com

2019 BMJ

84. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. (Abstract)

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.We did this double-blind, randomised, placebo-controlled trial (...) occurred in 47 (3·5%) of 1325 patients in the atrasentan group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85-2·07]; p=0·208). 58 (4·4%) patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75-1·59]; p=0·65).Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists

2019 Lancet Controlled trial quality: predicted high

85. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. (Abstract)

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes (...) participants were patients aged 18-85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12-20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation

2019 Lancet Controlled trial quality: predicted high

87. Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension

). The remaining studies considered different populations. One study included people with chronic renal insufficiency (mild to severe CKD), one study assessed people with CKD and kidney transplant patients, and one study included only people with IgA nephropathy. Four studies assessed ACR and PCR by using both tests to predict proteinuria at baseline, and then comparing these findings with long-term clinical outcomes. Outcomes measured varied between studies, but included all-cause mortality and kidney disease (...) Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available

2019 Health Technology Wales

88. Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease

Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

89. 100.57 Comparison of Coronary Artery Bypass Grafting and Drug-Eluting Stents in Patients With Chronic Kidney Disease and Left Main Coronary Artery Disease: A Systematic Review and Meta-Analysis. Full Text available with Trip Pro

100.57 Comparison of Coronary Artery Bypass Grafting and Drug-Eluting Stents in Patients With Chronic Kidney Disease and Left Main Coronary Artery Disease: A Systematic Review and Meta-Analysis. Redirecting

2019 JACC: Cardiovascular Interventions

90. General medicine: Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions?

activity mediates dehydration-induced renal injury . 15. Brooks DR , Ramirez-Rubio O , Amador JJ . CKD in Central America: a hot issue . 16. Jayasumana C , Gunatilake S , Senanayake P . Glyphosate, hard water and nephrotoxic metals: are they the culprits behind the epidemic of chronic kidney disease of unknown etiology in Sri Lanka? 17. Rampazzo N , Rampazzo Todorovic G , Mentler A , et al . Adsorption of glyphosate and aminomethylphosphonic acid in soils . 18. Ayoola S . Histopathological effects (...) General medicine: Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions? Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions? | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu

2019 Evidence-Based Medicine

91. General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation

General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation Article Text Commentary General medicine Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation David Massicotte-Azarniouch 1 , Manish M Sood 1 , 2

2019 Evidence-Based Medicine

92. Chronic Kidney Disease - Identification, Evaluation and Management of Adult Patients

renal disease (ESRD), often requiring dialysis or kidney transplantation , , . Most patients with chronic kidney disease die from other comorbidities before they progress to kidney failure. The outcome of many patients who go on to dialysis remains poor with 10 percent annual mortality; the overall 5 year survival rate is worse than that of most cancers . Evidence clearly indicates that control of hypertension and proteinuria can prevent or postpone kidney function decline . This underscores (...) and they often co-exist . Even if the cause seems obvious (e.g., diabetes), the possibility of a serious underlying primary renal disorder (e.g. glomerulonephritis) must be considered in patients with: Abnormal urinalysis, (e.g. proteinuria, hematuria, cellular casts). Note: hyaline casts are normal . Rapid sustained decline in kidney function (change in eGFR > 10-15%/year) despite remedy of reversible precipitants (e.g. volume contraction, febrile illness, medications). Constitutional symptoms suggesting

2019 Clinical Practice Guidelines and Protocols in British Columbia

93. Undernutrition in Chronic Kidney Disease

of the HEMO study. Kidney International 2004; 65: 2321-2334. 23. Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch W, Price R, Wanner C, Wang AYM, Wee P, Franch H. Aetiology of the protein energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism. Journal of Renal Nutrition 2013; 23: 77-90. 24. Koo JR, Park KY, Kim HJ, Che DW, Lee JS, Son BW, Rho JW. Depression in chronic haemodialysis patients (...) Undernutrition in Chronic Kidney Disease Clinical Practice Guideline Undernutrition in Chronic Kidney Disease Authors: Dr Mark Wright Consultant Nephrologist, St J am es ’s University Hospital, Leeds Mrs Elizabeth Southcott Senior Specialist Renal Dietitian, St J a m es’s University Hospital, Leeds Dr Helen MacLaughlin, Consultant Dietitian, Kings College Hospital Mr Stuart Wineberg Patient Representative Final Version: June 2019 Review Date: June 2024 2 Endorsements The National Institute

2019 Renal Association

94. Tonifying kidney, lung, and spleen combined with western medicine for stable chronic obstructive pulmonary disease: A systematic review Full Text available with Trip Pro

Western medicine versus conventional Western medicine in patients with stable chronic obstructive pulmonary disease: change in clinical effectiveness Figure 5: Comparison of tonifying kidney, lung, and spleen combined with conventional Western medicine versus conventional Western medicine in patients with stable chronic obstructive pulmonary disease: change in traditional Chinese medicine syndrome score Figure 6: Comparison of tonifying kidney, lung, and spleen combined with conventional Western (...) Tonifying kidney, lung, and spleen combined with western medicine for stable chronic obstructive pulmonary disease: A systematic review Tonifying kidney, lung, and spleen combined with western medicine for stable chronic obstructive pulmonary disease: A systematic review Liu YY, Gao Z - World J Tradit Chin Med Introduction: This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney, lung, and spleen ( TKLS ) combined with Western medicine for stable chronic

2019 World Journal of Traditional Chinese Medicine

95. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery Full Text available with Trip Pro

Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after cardiac surgery.To determine whether administration of nitric oxide reduces the incidence of postoperative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass.Two hundred and forty-four (...) group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronic kidney disease was reduced from 33% in the control group to 21% in the treatment group (RR, 0.64; 95% CI, 0.41-0.99; P = 0.024) and at 1 year, from 31% to 18% (RR, 0.59; 95% CI, 0.36-0.96; P = 0.017). Nitric oxide treatment reduced the overall major adverse kidney events at 30 days (RR, 0.40; 95% CI, 0.18-0.92

2018 EvidenceUpdates

96. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. Full Text available with Trip Pro

Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. Whether the increased incidence of chronic kidney disease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown.To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm Hg) versus the standard (...) in the setting of intensive SBP lowering was accompanied by decreases, rather than elevations, in levels of kidney damage biomarkers and thus may reflect benign changes in renal blood flow rather than intrinsic injury.National Institute for Diabetes and Digestive and Kidney Diseases.

2018 Annals of Internal Medicine

97. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment Full Text available with Trip Pro

Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines.To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease stage 3 or higher.A time-stratified propensity score-matched, population-based, prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol (≥300 mg/d) compared with those who did (...) groups. Use of allopurinol of at least 300 mg/d was associated with lower risk of developing chronic kidney disease stage 3 or higher compared with nonusers, with a hazard ratio (HR) of 0.87 (95% CI, 0.77-0.97). Allopurinol initiation at less than 300 mg/d was not associated with renal function decline (HR, 1.00; 95% CI, 0.91-1.09).In this large cohort, allopurinol initiation of at least 300 mg/d was associated with a lower risk of renal function deterioration. Because allopurinol does not appear

2018 EvidenceUpdates

98. Sonographic Venous Velocity Index Identifies Patients with Chronic Kidney Disease and Severe Diastolic Dysfunction Full Text available with Trip Pro

Sonographic Venous Velocity Index Identifies Patients with Chronic Kidney Disease and Severe Diastolic Dysfunction Diagnosing cardiorenal syndrome (CRS) in patients with chronic kidney disease (CKD) continues to remain challenging in outpatient practice. In this study, we investigate whether a newly developed venous velocity ultrasound index (VVI) can differentiate between patients with CRS and patients with CKD of other cause or normal renal function (NRF).Patients with CRS (n = 30), CKD (n=30 (...) ), and NRF (n=30) were included in the study. For each patient, duplex ultrasound scans of intrarenal segmental veins were retrospectively analyzed. The VVI was calculated from the renal venous doppler curve as the ratio of the maximal positive venous velocity to the maximal negative venous velocity. Patients with CRS were compared to age-matched controls with NRF and to GFR-matched controls with CKD.The GFRs of patients with CRS and those with CKD were comparable (26.4±5 and 25.6±7 ml/min/m2

2018 Ultrasound international open

99. PO-102 Meta-analysis of the effects of exercise on patients with chronic kidney disease Full Text available with Trip Pro

PO-102 Meta-analysis of the effects of exercise on patients with chronic kidney disease PO-102 Meta-analysis of the effects of exercise on patients with chronic kidney disease | Exercise Biochemistry Review Search / / / Proceedings Abstract Objective To systematically evaluate the impact of exercise on patients with chronic kidney disease Methods Computers were searched for PubMed, The cochrane Library, EMbase, CNKI, VIP, Medline, and WangFang Date for a decade between 2008 and 2018 to find out (...) about the effects of exercise on patients with chronic kidney disease (VO2peak, HDL, Cholesterol ). Aspects of the clinical randomized controlled trial (RCT). The included studies were evaluated for quality one by one, and the effects of the training group and the control group were meta-analyzed, and Meta analysis was performed using RevMan 5.3 software Results A total of 5 RCTs were included, including 386 patients. The results of the meta-analysis showed that the VO2peak experimental group

2018 Exercise Biochemistry Review

100. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial Full Text available with Trip Pro

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronic kidney disease are unknown.The UK HARP-III trial (United Kingdom Heart and Renal Protection-III), a randomized double-blind trial, included 414 (...) (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96-1.90), and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly different between randomized groups.Over 12 months, sacubitril/valsartan has similar effects on kidney function and albuminuria to irbesartan, but it has the additional effect of lowering blood pressure and cardiac biomarkers in people with chronic kidney disease.URL: http://www.isrctn.com . Unique identifier: ISRCTN11958993.

2018 EvidenceUpdates